Cervomed Inc. (CRVO) Stock Price & Analysis
Cervomed Inc. (CRVO) fell 1.17% to USD 2.53 as of September 9, 2026 at 10:47 UTC, according to Nexqual real-time market data.
CRVO last closed at USD 2.56; the session ranged USD 2.42–2.58 on volume of 392,643 shares. Market capitalization is $38.25M, with a 52-week range of USD 2.13–10.48 (NCM). Source: Nexqual, September 9, 2026 at 10:47 UTC.
Key Statistics (as of September 9, 2026 at 10:47 UTC)
| Price | USD 2.53 |
|---|---|
| Change | ▼ 1.17% (down) |
| Previous Close | USD 2.56 |
| Open | USD 2.58 |
| Day Range | USD 2.42 – 2.58 |
| 52-Week Range | USD 2.13 – 10.48 |
| Volume | 392,643 shares |
| Market Cap | $38.25M |
| Exchange | NCM |
Technical Analysis (CRVO)
Nexqual's technical model rates CRVO "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 10:47 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41 (neutral) |
| vs SMA50 | Below (USD 2.87) |
| MACD | -0.08 (negative) |
Analyst Ratings (CRVO)
Wall Street analysts rate CRVO "Strong Buy" based on 5 analysts, with a mean price target of USD 15.4 (range USD 7–25), per Nexqual as of September 9, 2026 at 10:47 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 15.4 |
| High Target | USD 25 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (CRVO)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.57 |
| Revenue Estimate | $50,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.64 vs est -0.86 ▲ beat |
| 2026-03-31 | USD -0.86 vs est -0.79 ▼ miss |
| 2025-12-31 | USD -0.88 vs est -0.7 ▼ miss |
| 2025-09-30 | USD -0.84 vs est -0.64 ▼ miss |
Source: Nexqual, September 9, 2026 at 10:47 UTC.
Financials & Fundamentals (CRVO)
| Total Revenue | $331,295 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -9406.96% |
| Profit Margin | +0.00% |
| ROE | -107.62% |
| Current Ratio | 8.57 |
| Total Cash | $24.94M |
| Total Debt | $0 |
| Free Cash Flow | $-16.29M |
Source: Nexqual, September 9, 2026 at 10:47 UTC.
Financial Health Score (CRVO)
Nexqual rates Cervomed Inc.'s overall financial health "Weak" across five dimensions, as of September 9, 2026 at 10:47 UTC.
| Growth | Critical — Revenue -59% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $25M cash, no debt |
| Cash Flow | Weak — FCF negative: -$16M, burning cash |
| Efficiency | Critical — ROE -108%, ROA -60.8% |
Ownership (CRVO)
| Insider Ownership | +26.43% |
|---|---|
| Institutional Ownership | +22.29% |
| Shares Outstanding | 15.12M |
| Float | 9.60M |
| Short % of Float | +7.87% |
Source: Nexqual, September 9, 2026 at 10:47 UTC.
Leadership (CRVO)
Cervomed Inc. is led by John J. Alam (age 63), Co-Founder, CEO, President & Director, per Nexqual as of September 9, 2026 at 10:47 UTC.
| Co-Founder, CEO, President & Director | John J. Alam (age 63) |
|---|---|
| Co-Founder & Director | Sylvie L. Gregoire Pharm.D. (age 64) |
| CFO, General Counsel & Corporate Secretary | William Robert Elder (age 42) |
| Executive Vice President of Clinical Development | Kelly Blackburn M.H.A. (age 61) |
| Executive Vice President of Technical Operations | Marinus Verwijs (age 49) |
Major Backers & Investors (CRVO)
Notable institutional backers of Cervomed Inc. include Woodline Partners LP, Sabby Management, LLC, Fidelity, according to Nexqual as of September 9, 2026 at 10:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Woodline Partners LP | 4.56% |
| Sabby Management, LLC | 1.65% |
| Fidelity | 0.62% |
| Byrne Asset Management LLC | 0.34% |
| Citizens Financial Group Inc/RI | 0.25% |
| Jane Street Group, LLC | 0.21% |
| Thompson Davis & Company Inc. | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.42% |
| BlackRock | 0.49% |
| Geode Capital | 0.44% |
Source: Nexqual, September 9, 2026 at 10:47 UTC.
From Cervomed Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
- The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
- Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
- Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TNON | Tenon Medical, Inc. | USD 3.36 | ▼ 10.88% |
| DWTX | Dogwood Therapeutics, Inc. | USD 2.04 | ▼ 13.56% |
| PEPG | PepGen Inc. | USD 3.21 | ▲ 0.94% |
| HCWB | HCW Biologics Inc. | USD 2.51 | ▼ 12.54% |
| QTTB | Q32 Bio Inc. | USD 11.69 | ▼ 8.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 10:47 UTC. This page is informational and not investment advice.